MindRank AI-Driven Drug Discovery Firm Recognized as Zhejiang Provincial Foreign-Invested R&D Center
MindRank
AI Drug Developer
Recently, the list of the second batch of provincial-level foreign-funded R&D centers in Zhejiang Province was announced. After independent applications by enterprises, the Provincial Department of Commerce and the Provincial Department of Science and Technology conducted reviews and confirmations with relevant units."MindRank" Selected as One of the "Second Batch of Provincial-level Foreign-funded R&D Centers in Zhejiang Province".A total of 35 foreign-funded enterprises in the province were selected for this evaluation, mainly concentrated in the fields of biomedicine, new materials, and artificial intelligence.
Foreign-funded R&D centers refer to institutions established by foreign investors for research and development and experimental development in natural sciences and related technological fields (including intermediate trials serving R&D activities). These centers are an important part of Zhejiang Province's "315" science and technology innovation system and a key platform for Zhejiang to actively connect with and integrate into the global industrial chain.
The selection of "MindRank" into the provincial-level foreign-invested R&D center this time is a follow-up to its previous inclusion...Zhejiang Province Science and Technology Small and Medium-sized Enterprises, Hangzhou "Eagle Plan" Enterprise, Hangzhou Innovative Small and Medium-sized Enterprises, Hangzhou Enterprise High-tech Research and Development CenterAnother important government qualification obtained, the company will continue to advance original research technology innovation and expand its global partner network, accelerating the application of AI pharmaceutical platform technology and the transformation of achievements.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug research and development, thereby helping more lives regain health.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Companies list as one of "China's most socially influential startups."
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Cooperation: bd@mindrank.ai
Other: info@mindrank.ai